As a general rule patients who have diffuse large B-cell lymphoma who relapse after initial treatment will be offered an autologous stem cell transplant as the preferred treatment. However not every patient is able, or willing to undergo a stem cell transplant.
There is no single treatment alternative to SCT that is universally accepted as the "best" option for everyone. Therefore on this page we will try to give you a list of treatment options that are being used for relapsed DLBC, and other aggressive forms of NHL. Please be sure to discuss them with your doctor if you find yourself in this situation.
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High-Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14
The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study
A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results